NetworkNewsBreaks – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) Schedules End of Phase 2 FDA Meeting, Initiates Phase 3 Development

Ritter Pharmaceuticals (NASDAQ: RTTR) shares are up 15% after the company said that the U.S. Food and Drug Administration (FDA) has agreed to an end of phase 2 meeting. The meeting is expected to take place in the third quarter of 2017 to discuss the results of Ritter’s recently completed phase 2b/3 trial, which demonstrated numerous positive topline results. A full analysis of the data is currently underway. The company also plans to discuss phase 3 plans in preparation of a New Drug Application (NDA) submission of RP-G28 for the treatment of lactose intolerance. “Based on the topline results of the study, I believe this instrument performed well in defining and capturing clinical benefits to patients with lactose intolerance. I am encouraged to see consistency in the data outcome measures and believe that the topline results provide data supporting a treatment benefit of this investigational compound,” Dr. William Chey, director of the GI Physiology Laboratory at University of Michigan, stated with regard to the study.

To view the full press release, visit: http://nnw.fm/1uAHP

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. Its lead product, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions worldwide. The company is further exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating/preventing a variety of conditions including: gastrointestinal diseases, immuno-oncology, metabolic, and liver disease. For more information, visit www.RitterPharma.com.

About NetworkNewsBreak

NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s